GSK's Malaria Vaccine To Be Piloted In Sub-Saharan Africa
This article was originally published in SRA
Executive Summary
GlaxoSmithKline's malaria vaccine, Mosquirix (RTS,S), is to be administered to young children in a limited number of African countries as part of a pilot scheme that could lead to wider deployment of the vaccine in three to five years, provided its safety and efficacy are shown to be acceptable.
You may also be interested in...
India’s Malaria Elimination Target May Be Tough To Meet, Say Experts
India has announced a plan to eliminate malaria by 2027, three years ahead of a global target set by the World Health Organization, but the deadline may be tough to meet without an accurate fix on the annual number of cases of the mosquito-borne disease, experts say.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.